Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
In 1979, the first prostate cancer patient was treated with a GnRH agonist at the Laval University Medical Center in Quebec City, Canada, thus rapidly leading to the worldwide replacement of surgical castration and high doses of estrogens. The discovery of medical castration with GnRH agonists was soon followed by fundamental changes in the endocrine therapy of prostate cancer. Most importantly, the excellent tolerance accompanying the treatment with GnRH agonists has been a key factor that permitted a series of studies demonstrating a major reduction in the death rate from prostate cancer ranging from 31 to 87% at 5 yr of follow-up in patients with localized or locally advanced prostate cancer. In fact, a one third reduction in prostate cancer deaths has been calculated in the metaanalysis of all available studies. The general acceptance of this discovery by patients and physicians is illustrated by world sales above 3.0 billion U.S. dollars in 2003. Although extremely efficient in achieving complete medical castration and well tolerated, with no other side effects than the expected hypoandrogenicity, GnRH agonists should not be administered alone. In fact, shortly after discovery of the castration effects of GnRH agonists, we observed that approximately 50% of androgens remain in the prostate after castration, thus leading to the recognition of the role of adrenal dehydroepiandrosterone as an important source of the androgens synthesized locally in the prostate and in many peripheral target tissues. We therefore developed combined androgen blockade (CAB), whereby the androgens of both testicular and adrenal origins are blocked simultaneously at start of treatment with the combination of a GnRH agonist to block the testis and a pure antiandrogen to block the action of the androgens produced locally. CAB, first used in advanced metastatic disease, has been the first treatment shown to prolong life in prostate cancer. Most interestingly, in 2002, we made the observation that CAB alone given continuously for 6.5 yr or more leads to cure of the disease in at least 90% of cases, thus suggesting that androgen blockade combining a GnRH agonist and a pure antiandrogen could well be the most efficient treatment of localized prostate cancer, and thus offering the possibility of practically eliminating death from prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Labrie, F. (1991) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(91)90116-a · Cited by 685
Self-citationLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544
Self-citationRhéaume, E., Lachance, Y., Zhao, H.-F., Breton, N., Dumont, M., Launoit, Y. D., Trudel, C., Luu-The, V., Simard, J., & Labrie, F. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-8-1147 · Cited by 362
Self-citationHERR, H. W., & O’SULLIVAN, M. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67533-7 · Cited by 250
Lachance, Y., Luu-The, V, Labrie, C., Simard, J., Dumont, M., de Launoit, Y., Guérin, S., Leblanc, G., & Labrie, F. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30528-8 · Cited by 201
Self-citationStructure of two in tandem human 17β-hydroxysteroid dehydrogenase genes
Luu-The, V., Labrie, C., Simard, J., Lachance, Y., Zhao, H.-F., Couët, J., Leblanc, G., & Labrie, F. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-2-268 · Cited by 173
Self-citationAndrogenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate.
LABRIE, C., BELANGER, A., & LABRIE, F. (1988) · Endocrinology · doi:10.1210/endo-123-3-1412 · Cited by 167
Self-citationLABRIE, Y., DUROCHER, F., LACHANCE, Y., TURGEON, C., SIMARD, J., LABRIE, C., & LABRIE, F. (1995) · DNA and Cell Biology · doi:10.1089/dna.1995.14.849 · Cited by 64
Self-citation
Cited by
Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 –isomerase gene family
Simard, J., Ricketts, M.-L., Gingras, S., Soucy, P., Feltus, F. A., & Melner, M. H. (2005) · Endocrine Reviews · doi:10.1210/er.2002-0050 · Cited by 620
Self-citationEnriori, P. J., Evans, A. E., Sinnayah, P., & Cowley, M. A. (2006) · Obesity · doi:10.1038/oby.2006.319 · Cited by 281
Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, Ö., Orwoll, E., Eriksson, A. L., Damber, J.-E., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061018 · Cited by 71
“In fact, the sex steroids made in peripheral tissues are inactivated locally into more water-soluble compounds (mainly glucuronidated metabolites for androgens) that diffuse into the general circulation where they can be measured.((3,18)) More precisely, it is now well established that uridine glucuronosyl transferase…”
BackgroundSelf-citationGauthier-Landry, L., Bélanger, A., & Barbier, O. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.009 · Cited by 62
Self-citation
Metadata
- Authors
- Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., & Candas, B.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2005-05-01
- Volume
- 26
- Issue
- 3
- Pages
- 361-379
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2086158679
- Cited by
- 170
- References
- 9
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.